Monitoring triple negative breast cancer therapy against lncRNA MANCR with MT218, a targeted MRMI contrast agent

Developing new molecular targeted therapies for triple negative breast cancer remains an obstacle. MANCR is a long noncoding RNA overexpressed in TNBC that sustains aggressive breast cancer growth. Silencing its expression with siRNA nanoparticles suppresses tumor growth, and treatment efficacy can be assessed by MRMI with a targeted contrast agent, MT218. Reduction in contrast-to-noise ratio following treatment confirmed effectiveness of siRNA therapy and allowed regular monitoring of tumor inhibition. RNA therapy shows promise as a new approach for treating aggressive breast cancer, and MRMI with the targeted contrast agent is a non-invasive imaging tool for TNBC detection and therapeutic surveillance.